Ameriprise’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-183,578
| Closed | -$7.39M | – | 4104 |
|
|
2026
Q1 | $7.39M | Sell |
183,578
-406,019
| -69% | -$8.75M | ﹤0.01% | 2159 |
|
|
2025
Q4 | $14.8M | Sell |
589,597
-128,106
| -18% | -$3.01M | ﹤0.01% | 1633 |
|
|
2025
Q3 | $16.2M | Sell |
717,703
-32,458
| -4% | -$757K | ﹤0.01% | 1552 |
|
|
2025
Q2 | $13M | Buy |
750,161
+283,500
| +61% | +$5.25M | ﹤0.01% | 1629 |
|
|
2025
Q1 | $10.2M | Sell |
466,661
-416,140
| -47% | -$11.5M | ﹤0.01% | 1754 |
|
|
2024
Q4 | $28.2M | Buy |
882,801
+22,507
| +3% | +$677K | 0.01% | 1141 |
|
|
2024
Q3 | $24.8M | Buy |
860,294
+76,380
| +10% | +$2.83M | 0.01% | 1211 |
|
|
2024
Q2 | $30.1M | Buy |
783,914
+252,552
| +48% | +$11.4M | 0.01% | 1039 |
|
|
2024
Q1 | $31.2M | Sell |
531,362
-34,218
| -6% | -$2.18M | 0.01% | 1035 |
|
|
2023
Q4 | $33.9M | Buy |
565,580
+213,188
| +60% | +$10.8M | 0.01% | 959 |
|
|
2023
Q3 | $13.4M | Buy |
352,392
+211,314
| +150% | +$9.28M | ﹤0.01% | 1485 |
|
|
2023
Q2 | $12.9M | Buy |
141,078
+61,405
| +77% | +$5.3M | ﹤0.01% | 1581 |
|
|
2023
Q1 | $5.26M | Buy |
79,673
+22,033
| +38% | +$1.27M | ﹤0.01% | 2291 |
|
|
2022
Q4 | $2.98M | Buy |
57,640
+1,099
| +2% | +$58.3K | ﹤0.01% | 2612 |
|
|
2022
Q3 | $3.86M | Sell |
56,541
-122,163
| -68% | -$7.23M | ﹤0.01% | 2405 |
|
|
2022
Q2 | $8.08M | Buy |
178,704
+9,083
| +5% | +$414K | ﹤0.01% | 1909 |
|
|
2022
Q1 | $8.62M | Buy |
169,621
+2,933
| +2% | +$129K | ﹤0.01% | 2038 |
|
|
2021
Q4 | $7.88M | Sell |
166,688
-36,024
| -18% | -$1.42M | ﹤0.01% | 2159 |
|
|
2021
Q3 | $6.68M | Buy |
202,712
+68,555
| +51% | +$3.85M | ﹤0.01% | 2180 |
|
|
2021
Q2 | $8.48M | Buy |
+134,157
| New | +$6.92M | ﹤0.01% | 2063 |
|
|
2020
Q1 | – | Sell |
-19,200
| Closed | -$589K | – | 3636 |
|
|
2019
Q4 | $589K | Sell |
19,200
-1,300
| -6% | -$36K | ﹤0.01% | 3277 |
|
|
2019
Q3 | $494K | Sell |
20,500
-67,670
| -77% | -$1.86M | ﹤0.01% | 3307 |
|
|
2019
Q2 | $2.23M | Buy |
88,170
+40,112
| +83% | +$816K | ﹤0.01% | 2681 |
|
|
2019
Q1 | $937K | Buy |
+48,058
| New | +$756K | ﹤0.01% | 3066 |
|
Other funds holding APLS
Ameriprise's APLS Position: Q2 2026 in Review
Ameriprise sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 183,578 shares — an estimated $7.39M sold.
Ameriprise first reported a position in APLS in Q1 2019 and held it in 24 quarters. The position peaked at $33.9M in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Ameriprise reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Ameriprise sold 183,578 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.39M.
- Ameriprise first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 24 quarters.
- Ameriprise's Apellis Pharmaceuticals position peaked at $33.9M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.